Totus Medicines closes $66M Series B to fund early-stage PI3Ka inhibitor, names new CEO

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and CEO.

The Emeryville, CA-based Totus, which emerged with a $40 million Series A in December 2021, closed…
Click here to view original post